Evidence map›Paper›PMID 12788538›Full record

ReviewAdvanced drug delivery reviews2003

Emerging significance of plasmid DNA nuclear import in gene therapy.

Felix M Munkonge, David A Dean, Elizabeth Hillery, Uta Griesenbach, Eric W F W Alton

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Felix M MunkongeDepartment of Gene Therapy, National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, UK. f.munkonge@imperial.ac.uk
David A Dean
Elizabeth Hillery
Uta Griesenbach
Eric W F W Alton

Funding

VASCULAR SMOOTH MUSCLE SPECIFIC GENE THERAPY VECTORSR01HL059956 · NHLBI · UNIVERSITY OF SOUTH ALABAMA · PI DEAN, DAVID A · 1998 to 2007
$1.8M
NUCLEAR TARGETING VECTORS FOR CORNEAL GENE THERAPYR01EY012962 · NEI · UNIVERSITY OF SOUTH ALABAMA · PI DEAN, DAVID A · 2000 to 2003
$1.1M
NEI NIH HHS R01 EY012962NHLBI NIH HHS R01 HL059956
6 · The paper itself

Abstract

The signal-mediated import of plasmid DNA (pDNA) into nondividing mammalian cell nuclei is one of the key biological obstacles to nonviral therapeutic pDNA delivery. Overcoming this barrier to pDNA transfer is thus an important fundamental objective in gene therapy. Here, we outline the rationale behind current and future strategies for signal-mediated pDNA nuclear import. Results obtained from studies of the nuclear delivery of pDNA coupled to experimentally defined nuclear localisation signal (NLS) peptides, in conjunction with detergent-permeabilised reconstitution cell assays, direct intracellular microinjection, cell-based transfection, and a limited number of in vivo experiments are discussed.

Indexed as

Active Transport, Cell NucleusAnimalsCell NucleusGenetic TherapyHumansPlasmids

Identifiers

PMID12788538
PMCPMC13416894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.